BayRab Articles
Crucell evaluating MAb against rabies
22 November 2004
Bayer Biologicals moves to stop counterfeiting
26 July 2004
Showing 1-2 of 2 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
